Joel Greenblatt's BMRN Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 265,332 shares of BioMarin Pharmaceutical Inc. (BMRN) worth $14.37 M, representing 0.06% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 45 quarters.
Based on 13F filings since 2013, Joel Greenblatt has maintained a long-term strategic position in BMRN, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2025, adding 145,886 shares. Largest reduction occurred in Q4 2024, reducing 11,661 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's BioMarin Pharmaceutical (BMRN) Holding Value Over Time
Track share changes against reported price movement
Quarterly BioMarin Pharmaceutical (BMRN) Trades by Joel Greenblatt
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2014 | +3,885 | New Buy | 3,885 | $72.07 |
| Q4 2014 | -3,885 | Sold Out | 3,885 | $0.00 |
| Q1 2015 | +4,195 | New Buy | 4,195 | $124.67 |
| Q2 2015 | -4,195 | Sold Out | 4,195 | $0.00 |
| Q2 2016 | +3,144 | New Buy | 3,144 | $77.93 |
| Q3 2016 | -3,144 | Sold Out | 3,144 | $0.00 |
| Q3 2017 | +3,590 | New Buy | 3,590 | $93.04 |
| Q4 2017 | -3,590 | Sold Out | 3,590 | $0.00 |
| Q4 2019 | +8,160 | New Buy | 8,160 | $84.56 |
| Q1 2020 | +2,860 | Add 35.05% | 11,020 | $84.48 |
| Q2 2020 | -5,178 | Reduce 46.99% | 5,842 | $123.42 |
| Q3 2020 | -5,842 | Sold Out | 5,842 | $0.00 |
| Q3 2021 | +3,241 | New Buy | 3,241 | $77.14 |
| Q4 2021 | -3,241 | Sold Out | 3,241 | $0.00 |
| Q1 2023 | +3,758 | New Buy | 3,758 | $97.24 |
| Q2 2023 | -3,758 | Sold Out | 3,758 | $0.00 |
| Q3 2023 | +4,056 | New Buy | 4,056 | $88.48 |
| Q4 2023 | -1,610 | Reduce 39.69% | 2,446 | $96.42 |
| Q1 2024 | -2,446 | Sold Out | 2,446 | $0.00 |
| Q3 2024 | +23,395 | New Buy | 23,395 | $70.29 |
| Q4 2024 | -11,661 | Reduce 49.84% | 11,734 | $65.73 |
| Q1 2025 | +35,735 | Add 304.54% | 47,469 | $70.69 |
| Q2 2025 | +71,977 | Add 151.63% | 119,446 | $54.97 |
| Q3 2025 | +145,886 | Add 122.14% | 265,332 | $54.16 |
Joel Greenblatt's BioMarin Pharmaceutical Investment FAQs
Joel Greenblatt first purchased BioMarin Pharmaceutical Inc. (BMRN) in Q3 2014, acquiring 3,885 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held BioMarin Pharmaceutical Inc. (BMRN) for 45 quarters since Q3 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt's largest addition to BioMarin Pharmaceutical Inc. (BMRN) was in Q3 2025, adding 265,332 shares worth $14.37 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 265,332 shares of BioMarin Pharmaceutical Inc. (BMRN), valued at approximately $14.37 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, BioMarin Pharmaceutical Inc. (BMRN) represents approximately 0.06% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt's peak holding in BioMarin Pharmaceutical Inc. (BMRN) was 265,332 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.